62 research outputs found
PCV81 AN ECONOMIC EVALUATION OF THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY IN TERMS OF OPTIMAL LIPID VALUE ATTAINMENT
Get PDFDigitalitzat per Artypla
PCV74 PREDICTED REDUCTION IN HOSPITAL DAYS AND ASSOCIATED COSTS AMONG MANAGED CARE PRIMARY AND SECONDARY RISK MIXED DYSLIPIDEMIA PATIENTS TREATED WITH FIXED DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN COMBINATION THERAPY
Get PDFPCV15 COMBINED OPTIMAL LIPID VALUE GOAL ATTAINMENT AFTER TREATMENT INITIATION WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS EZETIMIBE PLUS SIMVASTATIN COMBINATION THERAPY IN A MANAGED CARE PATIENT POPULATION WITH PRIOR CARDIOVASCULAR DISEASE IN THE UNITED STATES
Get PDFPCV25 IMPROVEMENTS IN CARDIOVASCULAR DISEASE OUTCOMES IN MANAGED CARE PATIENTS MANAGED ACCORDING TO NATIONAL LIPID TREATMENT GUIDELINES
Get PDFA comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin
Get PDFPharmacological primary and secondary cardiovascular prevention among diabetic patients in a multiethnic general practice population: still room for improvements
Get PDF
PCV7 ASSOCIATION BETWEEN DEYO-CHARLSON COMORBIDITY INDEX SCORE AND SUBSEQUENT CARDIOVASCULAR DISEASE EVENTS AND ASSOCIATED COST IN DYSLIPIDEMIA MANAGEMENT AMONG MANAGED CARE PATIENTS IN THE UNITED STATES
Get PDFPCV49 DEVELOPMENT OF AN INTERACTIVE MODEL TO PREDICT LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL) REDUCTION AND LDL GOAL ATTAINMENT ASSOCIATED WITH STATIN USE IN ROUTINE CLINICAL PRACTICE
Get PDFPCV9 CARDIOVASCULAR EVENT REDUCTION AFTER TREATMENT WITH SIMVASTATIN PLUS NIACIN EXTENDED-RELEASE COMBINATION THERAPY VERSUS GENERIC SIMVASTATIN THERAPY FROM A MANAGED CARE ORGANIZATION'S PERSPECTIVE IN THE UNITED STATES
No full text- …
